Pfizer Inc. and Ligand Pharmaceuticals Incorporated: A Detailed Gross Profit Analysis

Pfizer vs. Ligand: A Decade of Gross Profit Trends

__timestampLigand Pharmaceuticals IncorporatedPfizer Inc.
Wednesday, January 1, 20145540200040028000000
Thursday, January 1, 20156610700039203000000
Friday, January 1, 201610340200040495000000
Sunday, January 1, 201713573600041306000000
Monday, January 1, 201824511600042399000000
Tuesday, January 1, 201910893500041531000000
Wednesday, January 1, 202015600000033216000000
Friday, January 1, 202121495700050467000000
Saturday, January 1, 202214341800065986000000
Sunday, January 1, 20239626500028809000000
Monday, January 1, 202445776000000
Loading chart...

Data in motion

A Decade of Gross Profit: Pfizer Inc. vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Pfizer Inc. and Ligand Pharmaceuticals from 2014 to 2023. Pfizer, a global giant, consistently outperformed Ligand, with its gross profit peaking in 2022 at approximately 66 billion, a staggering 1,200% higher than Ligand's peak in 2018. However, Ligand showed remarkable growth, with its gross profit increasing by over 340% from 2014 to 2018. The data reveals Pfizer's dominance, yet Ligand's growth trajectory highlights its potential in the market. Notably, Pfizer's gross profit saw a significant dip in 2023, dropping to around 29 billion, indicating potential market challenges. This comparative analysis offers valuable insights into the financial health and strategic positioning of these pharmaceutical leaders.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025